Friday 7 September 2012
Quality of Life and Care of People with Dementia across the Trajectory of the Disease
Session 0900 – 1300
Cost $145 (Includes welcome coffee and morning tea)
What is Quality of Life and does it matter for people with dementia and carers?
The workshop will present QOL research on diagnosis, respite care and residential care from four leading presenters, and in addition you will hear the perspective of a person with dementia speaking on QOL. A panel discussion.
Dr Maria O’Reilly – DCRC-CC Queensland University of Technology
“What is quality of life and why should we care?”
Professor Wendy Moyle – Griffith University and DCRC-CC, Queensland University of Technology
“What do we know about quality of life and how do we know it?”
Professor Elizabeth Beattie – DCRC-CC, Queensland University of Technology
“So what? How can we translate an understanding of quality of life into practice?”
Nurses and Allied Health Professionals are welcome to participate.
This symposia is co-sponsored by IPA and the Queensland Dementia Training Study Centre
Young Onset Dementia – FULLY BOOKED
Session 1330 – 1730
Cost $245 (Includes afternoon tea)
Presenter Dr Raymond Koopmans
The IPA taskforce for people with Young Onset Dementia (YOD), in cooperation with the Australian Alzheimer Association, presents a pre-conference workshop entitled: “Towards appropriate care and services for people with Young Onset Dementia”. The goal of the workshop is to formulate preliminary recommendations on what good care for people with YOD comprises. Issues that will be addressed are: “What is necessary for good service delivery?” (Adrienne Withall), psychosocial care for people with YOD (Meredith Gresham), educational issues (Wendy Moyle), quality of life and predictors of institutionalisation (Christian Bakker), worldwide survey on services (Christophe van Dijken in cooperation with Alzheimer Disease International), and psychotropic drug use in community dwelling and institutionalised people with YOD (Raymond Koopmans).
Saturday 8 September 2012
Introduction to Interpersonal Psychotherapy for Depressed Older Adults
Session 0900 – 1600
Cost $395 (Includes morning / afternoon teas and lunch)
Presenter Dr Greg Hinrichsen
In the treatment of depression, Interpersonal Psychotherapy (IPT) is frequently mentioned as a time-limited psychotherapy because of its well-established efficacy in many large-scale treatment studies. Other studies have found IPT useful in the treatment of acute late life depression and in prevention of its recurrence. Clinical reports indicate that IPT is easily adapted to older adults, is relevant to the most common problems evident among depressed older people, and may have rates of success that are similar to those found in clinical research trials. IPT is a manualized psychotherapy. IPT is typically conducted in 16 sessions in three phases of treatment with a focus on one or two interpersonally-relevant problem areas: Grief (complicated bereavement), Interpersonal Role Disputes (conflicts with a significant other), Role Transitions (changes in a life situation), and Interpersonal Deficits (those individuals lacking social skills necessary for initiating or sustaining relationships). Treatment goals and strategies are outlined for each problem area. In this seven hour, interactive, introductory workshop, participants will be taught the basic goals, strategies, and techniques of IPT. Videotaped sessions in which IPT is conducted with depressed older adults will be presented and discussed with participants. Clinical case material will also be draw from the clinical treatment manual for older adults, Interpersonal Psychotherapy for Depressed Older Adults (Hinrichsen & Clougherty, 2006)
Neuropsychiatric Symposium on Parkinson’s Disease – FULLY BOOKED
Session 0900 – 1300
Cost $245 (Includes morning tea)
Presenter Professor Sergio Starkstein
Depression is a frequent finding in Parkinson’s disease (PD), with prevalence of about 20% and a 1-year incidence of 10-20% for DSM-IV major depression. Cross- sectional studies demonstrated a significant association between depression and worse quality of life, increased mortality, and increased burden for caregivers. Longitudinal studies demonstrated that depression in PD is associated with a faster cognitive, motor and functional decline. Preliminary studies suggest that loss of dopamine and norepinephrine innervation in the locus coeruleus, cingulate gyrus and ventral striatum may be related to depression in PD. Recent studies suggest the efficacy of escitalopram, nortriptyline and pramipexole to treat depression in PD, but side effects may limit the usefulness of these medications. Preliminary data suggest that cognitive behavioural therapy may be an adequate treatment modality for well-motivated patients and for those with drug contraindications or side-effects. Apathy is another frequent non-motor problem in PD and is significantly associated with depression and cognitive deficits. There is discrepant information as to whether apathy is a sequel of deep brain stimulation, and its mechanism remains unknown. Specific psychotherapeutic techniques should be developed to treat this condition.